Highlights Newsletter 3 This newsletter presents you the following key sessions: Update of the third planned survival analysis of the KEYNOTE-045 trial showing a continued OS benefit of pembrolizumab compared with chemotherapy among patients with advanced urothelial cancer with no new safety signals. Video-interview with Professor Ronald de Wit, oncologist, Erasmus Medical Centre, The Netherlands Alectinib delays disease progression for a significant 15 months longer than crizotinib in the first-line treatment of advanced ALK-positive NSCLC Olaparib delays disease progression in BRCA-mutated metastatic breast cancer Immunotherapy is effective in the treatment of relapsed mesothelioma, according to results of the MAPS-2 phase II trial Patients with advanced cancer live a significant 5 months longer using a web-based system for realtime self-reported symptoms Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: promising preliminary phase I/II results of ECHO-202/KEYNOTE-037